CARVYKTI® (ciltacabtagene autoleucel) Reduces Risk of Disease Progression or Death by 74 Percent in Earlier-Line Multiple Myeloma Treatment in the Landmark Phase 3 CARTITUDE-4 Study

/PRNewswire/ -- The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that results from the Phase 3 CARTITUDE-4 study showed CARVYKTI®...

Related Keywords

United States ,Chicago ,Illinois ,American ,Satu Glawe ,Binod Dhakal ,Hemophagocytic Lymphohistiocytosis ,Legend Biotech United States Inc ,National Cancer Institute ,European Commission ,Congress Abstract ,None Of Janssen Research Development ,Exchange Commission ,American Cancer Society ,Division Of Hematology ,Janssen Biotech Inc ,European Medicines Agency ,European Hematology Association ,Janssen Pharmaceutical Companies Of Johnson ,Janssen Research Development ,College Of Wisconsin ,Janssen Pharmaceutical Companies ,American Society Of Clinical Oncology ,American Society Of Clinical Oncology Annual Meeting ,Companies Of Johnson ,Drug Administration ,Johnson ,New England Journal ,Clinical Oncology ,Annual Meeting ,Thenew England Journal ,Hybrid Congress ,Associate Professor ,Medical College ,Hazard Ratio ,Confidence Interval ,Janssen Biotech ,Legend Biotech United States ,Release Syndrome ,Effector Cell Associated Neurotoxicity Syndrome ,Macrophage Activation Syndrome ,Risk Evaluation ,Mitigation Strategy ,Mediated Myelitis ,Nerve Palsies ,Recurrent Cytopenias ,Hypersensitivity Reactions ,Use Machines ,Boxed Warning ,Pharmaceutical Companies ,Infectious Diseases ,Janssen Research ,Private Securities Litigation Reform Act ,Annual Report ,Note Regarding Forward Looking ,Quarterly Reports ,Clinical Oncology Annual ,Study Comparing ,Versus Pomalidomide ,Participants With Relapsed ,Lenalidomide Refractory Multiple Myeloma ,Multiple Myeloma ,Plasma Cell ,Accessed May ,Statistics About Multiple Myeloma ,The Janssen Pharmaceutical Companies Of Johnson Amp ,